|
Organization And Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified |
12 Months Ended | 12 Months Ended | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Dec. 31, 2011
Warrants Expiring In 2011 [Member]
|
Dec. 31, 2011
Warrants Expiring In 2013 [Member]
|
Dec. 31, 2011
Warrants Expiring In 2014 [Member]
|
Dec. 31, 2011
Warrants Expiring In 2016 [Member]
|
Dec. 31, 2011
May 2011 Convertible Senior Notes [Member]
|
Apr. 30, 2006
May 2011 Convertible Senior Notes [Member]
|
Dec. 31, 2011
May 2013 Convertible Senior Notes [Member]
|
Apr. 30, 2006
May 2013 Convertible Senior Notes [Member]
|
Dec. 31, 2011
May 2014 Convertible Senior Notes [Member]
|
Jul. 31, 2010
May 2014 Convertible Senior Notes [Member]
|
Dec. 31, 2011
May 2016 Convertible Senior Notes [Member]
|
Dec. 31, 2011
April 2021 Senior Unsecured Notes [Member]
|
Mar. 31, 2011
April 2021 Senior Unsecured Notes [Member]
|
Dec. 31, 2011
Convertible Senior Notes [Member]
|
Dec. 31, 2010
Convertible Senior Notes [Member]
|
Dec. 31, 2011
December 2014 Senior Unsecured Notes, December 2016 Senior Unsecured Notes, December 2021 Senior Unsecured Notes And December 2041 Senior Unsecured Notes [Member]
|
Dec. 31, 2011
Greater Than 120 Days Past Due [Member]
|
Dec. 31, 2011
Greater Than 365 Days Past Due [Member]
|
Dec. 31, 2011
Accounts Receivables [Member]
|
|
| Organization And Summary Of Significant Accounting Policies [Line Items] | ||||||||||||||||||||||
| Advertising expenses | $ 116,600,000 | $ 116,500,000 | $ 108,100,000 | |||||||||||||||||||
| Conversion price of notes | $ 38.75 | $ 38.75 | $ 38.10 | $ 38.10 | $ 45.08 | $ 45.08 | $ 45.41 | |||||||||||||||
| Warrants exercise price | 50.80 | 53.90 | 56.76 | 60.10 | ||||||||||||||||||
| Weighted-average shares of common stock outstanding excluded from the computation of diluted net income per share because their effect was antidilutive | 21.1 | 22.5 | 17.4 | |||||||||||||||||||
| Percentage of fair value of securities sold and collateralized by U.S. government securities | 102.00% | |||||||||||||||||||||
| Accounts receivables, amount past due | 612,400,000 | 250,700,000 | ||||||||||||||||||||
| Accounts receivable, days past due | 120 | 365 | ||||||||||||||||||||
| Total Accounts Receivable due from Greece, Italy, Portugal and Spain | 1,100,000,000 | |||||||||||||||||||||
| Purchase cost of royalties interest paid | 525,000,000 | |||||||||||||||||||||
| Percentage share cost of royalty interest paid | 65.00% | |||||||||||||||||||||
| Percentage share cost of royalty interest by Royalty Pharma | 35.00% | |||||||||||||||||||||
| Prepaid royalties capitalized | 341,300,000 | |||||||||||||||||||||
| Unamortized prepaid royalty asset | 190,200,000 | 219,500,000 | ||||||||||||||||||||
| Amortized to cost of goods sold | 29,300,000 | 25,500,000 | 29,900,000 | |||||||||||||||||||
| Unamortized capitalized software costs | 96,000,000 | 22,500,000 | ||||||||||||||||||||
| Net transaction losses | 21,300,000 | 3,700,000 | 16,400,000 | |||||||||||||||||||
| Carrying value of the convertible notes | 2,920,000,000 | 3,480,000,000 | ||||||||||||||||||||
| Carrying value of the senior unsecured notes | 7,605,734,000 | 2,838,573,000 | 992,100,000 | 3,690,000,000 | ||||||||||||||||||
| Debt Instrument, Fair Value | 1,060,000,000 | 3,530,000,000 | 3,970,000,000 | 3,930,000,000 | ||||||||||||||||||
| Principal amount of senior notes | $ 650,000,000 | $ 650,000,000 | $ 1,250,000,000 | $ 1,000,000,000 | $ 3,700,000,000 | |||||||||||||||||